Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban
Technology appraisal guidance
Reference number: TA697
Published:
Last updated:
Following the appraisal committee meeting on 9 June 2020 further work is required to establish the next steps for the appraisal. Timelines are therefore on hold and an update will be provided when the next steps are confirmed.